Can Gene Expression Predict if a Brain Tumor Is Likely to Grow Back?
A gene expression test can accurately predict the best treatment for meningioma patients by measuring the aggressiveness of their tumors and adjusting treatment accordingly.
University of California San Francisco
Give to UCSFA gene expression test can accurately predict the best treatment for meningioma patients by measuring the aggressiveness of their tumors and adjusting treatment accordingly.
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
Laura Esserman discusses breast cancer risk factors, progress in the field and the importance of tailoring treatment for women with low-risk cancer while also identifying women at high risk of invasive cancer.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
Researchers have found that people who developed breast, ovary, skin and uterine cancers have significantly higher levels of endocrine-disrupting chemicals in their bodies.
Engineered immune cells. Supercharged scans. Drug implants. Gene manipulators. Blood biopsies. Read how these breakthroughs are transforming cancer care.
A new treatment approach draws on research into the unique teenage brain.
Two UCSF scientists – James Gardner, MD, PhD, and Rebeca de Pavia Fróes Rocha, PhD – have received Pew awards for their work in immunology as part of a program that supports promising early-career investigators.
UCSF researchers developed an approach to measure an over-the-counter allergy medication’s effectiveness in repairing brain damage from multiple sclerosis (MS), making it possible to also assess future therapies for the disorder.
Laws in many states require notifying women if they have dense breasts, a risk factor for breast cancer. But density shouldn’t be the only factor in determining whether supplemental screening is
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
Taking into account genetic factors that can change PSA levels not associated with cancer, the screening accuracy can be improved.
UCSF scientists have found that brain cancer glioblastoma can cause cognitive decline by affecting neural connections, but the epilepsy drug gabapentin shows promise in blocking this activity, offering hope for new treatments.
Transgender women keep their prostates even after gender-affirming surgery, and the estimated risk of prostate cancer is at about 14 cases per 10,000 people.
Medical centers can reduce their carbon footprint and expenses by up to 51% by turning off MRIs and using a “power save” mode that cycles cooling components on and off.
Leading cancer researchers from UCSF will present at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 14-19, 2023, in Orlando.
Thermo Fisher Scientific Inc. and UCSF will accelerate advanced cell therapies for difficult to treat conditions like cancer from a new manufacturing facility.
A clinical trial showed that, rather than removing lymph nodes, leaving them intact could help immunotherapy activate tumor-fighting T cells in the lymph nodes.
For the past 30 years, the California Tobacco Control Program has helped Californians save $816 billion in health care costs.
In a first, UCSF scientists created a molecular-level, 3D picture of how an odor molecule activates a human odorant receptor.
A new digital tool helps to calculate breast cancer risk for those who may develop advanced cancer that goes undiagnosed despite regular screenings.
Sick leave coverage expansion were associated with higher rates of mammography screening and colorectal screening, potentially leading to better health outcomes.
The WISDOM 2.0 study aims to transform breast cancer screening by using a personalized approach and will expand to women as young as 30.